News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,028 Results
Type
Article (39736)
Company Profile (248)
Press Release (660044)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204186)
Career Advice (2008)
Deals (35420)
Drug Delivery (95)
Drug Development (81053)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345227)
Policy (32546)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (95)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (132)
Approvals (16187)
Artificial intelligence (264)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2320)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (155)
Cell therapy (436)
Cervical cancer (20)
Clinical research (66092)
Collaboration (857)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (250)
Cystic fibrosis (102)
Data (2337)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (103)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87066)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112662)
Executive appointments (741)
FDA (17570)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (771)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (719)
Government (4430)
Grass and pollen (4)
Guidances (162)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16526)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (476)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (328)
MASH (77)
Medical device (13384)
Medtech (13389)
Mergers & acquisitions (19467)
Metabolic disorders (707)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1941)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57345)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20593)
Phase II (29111)
Phase III (21676)
Pipeline (1385)
Policy (147)
Postmarket research (2563)
Preclinical (8761)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (384)
Real estate (5907)
Recruiting (65)
Regulatory (22328)
Reports (47)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (131)
Series B (90)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (50)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (173)
Last 7 days (951)
Last 30 days (3190)
Last 365 days (32534)
2025 (11924)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37883)
Australia (6193)
California (6422)
Canada (2065)
China (539)
Colorado (274)
Connecticut (281)
Delaware (158)
Europe (81414)
Florida (957)
Georgia (215)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (172)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (922)
Massachusetts (4772)
Michigan (226)
Minnesota (404)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1807)
North Carolina (990)
North Dakota (8)
Northern California (2837)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1429)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2411)
Tennessee (106)
Texas (951)
United States (24051)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (56)
700,028 Results for "otonomy inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Otonomy Announces Change in Stock Exchange Listing
Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022.
December 22, 2022
·
1 min read
Deals
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.
March 29, 2023
·
4 min read
Business
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Otonomy, Inc. reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities.
November 10, 2022
·
7 min read
Biotech Beach
Otonomy Provides Corporate Update - December 19, 2022
Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.
December 19, 2022
·
6 min read
Press Releases
CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
May 8, 2025
·
4 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Press Releases
Exagen Inc. Prices Public Offering of Common Stock
May 8, 2025
·
3 min read
Press Releases
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
May 7, 2025
·
5 min read
Biotech Beach
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy, Inc. announced that management will participate in the following virtual investor conference events.
February 28, 2022
·
1 min read
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
1 of 70,003
Next
